Abstract: The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.

Abstract: The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.

Abstract: The present invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as pharmaceutical compositions, preparation methods, and uses thereof. The MAGL small molecule inhibitors are represented by formula (I), with specific substituents and definitions as described in the specification. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. The invention includes these compounds or their pharmaceutical compositions for the treatment and/or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and/or pain-associated spasticity.

Abstract: The present disclosure is directed to a class of Sigma-1 receptor small molecule antagonists, their pharmaceutical compositions, preparation methods, and uses. The Sigma-1 receptor small molecule antagonists are shown in formula (I), with specific substituents and definitions described in the specification. These Sigma-1 receptor small molecule antagonists exhibit good binding and antagonistic activity with the Sigma-1 receptor. The invention includes these compounds or their pharmaceutical compositions and their use in treating and/or preventing pain disorders related to the Sigma-1 receptor.

Abstract: The invention discloses a nitrogen-containing heterocyclic derivative of a somatostatin receptor subtype 4 (SSTR4) small molecule agonist and its pharmaceutical composition, preparation method, and use. The nitrogen-containing heterocyclic derivative of the SSTR4 small molecule agonist is represented by formula (I), and the specific substituents and definitions are as described in the specification. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists exhibit good binding and agonistic activities with SSTR4. Such compounds or their pharmaceutical compositions have great potential in treating and/or preventing pain disorders related to SSTR4 receptor.

Abstract: The present invention provides compounds which are selective kappa-opioid receptor agonist, method of preparation of these compounds, compositions that comprise these compounds, and methods for treating kappa-opiod receptor agonist related medical disorders.

Abstract: The present invention provides compounds which are selective kappa-opioid receptor agonist, method of preparation of these compounds, compositions that comprise these compounds, and methods for treating kappa-opiod receptor agonist related medical disorders.

Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.

Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.

Abstract: The present invention provides compounds which are selective kappa-opioid receptor agonist, method of preparation of these compounds, compositions that comprise these compounds, and methods for treating kappa-opiod receptor agonist related medical disorders

Abstract: The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.

Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.

Abstract: Processes for preparing 3-substituted phenylalkylamines comprising reacting a phenyl boronic compound with an ?-? unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction, followed by reductive alkylation. The processes may be useful in the synthesis of tapentadol.

Abstract: The invention provides methods for preparing substituted phenylalkanes. In particular, the processes comprise reacting a phenyl boronic compound with an ?-? unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction. The processes may be useful in the synthesis of tapentadol.

Abstract: Processes for preparing 3-substituted phenylalkylamines comprising reacting a phenyl boronic compound with an ?-? unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction, followed by reductive alkylation. The processes may be useful in the synthesis of tapentadol.

Abstract: The invention provides methods for preparing substituted phenylalkanes. In particular, the processes comprise reacting a phenyl boronic compound with an ?-? unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction. The processes may be useful in the synthesis of tapentadol.

Abstract: The present invention provides processes for preparing normorphinans from N-substituted morphinans. In particular, the invention provides methods for removing the N-substituent from the N-substituted morphinan to from a normorphinan carbamate, and then removing the carbamate functionality from the normorphinan carbamate to form the normorphinan.

Abstract: The present invention provides processes for preparing normorphinans from N-substituted morphinans. In particular, the invention provides methods for removing the N-substituent from the N-substituted morphinan to from a normorphinan carbamate, and then removing the carbamate functionality from the normorphinan carbamate to form the normorphinan.

Abstract: The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis/alkylation reactions for the synthesis of N-alkyl morphinans.

Abstract: The present invention provides processes for the demethylation of an N-methyl morphinan comprising a ketone functional group. In particular, the invention provides methods for the protection of the ketone functional group such that impurities are not generated during the demethylation of the N-methyl morphinan.